NHD Global
Growth Hormone & IGF · Source-reviewed dossier
Source-Reviewed Research Dossier
IGF-1 LR3 is a lab-made version of insulin-like growth factor-1, a natural signal that helps cells grow and handle nutrients. LR3 has small changes that alter how it binds to IGF-binding proteins. In a 2023 yeast production study, purified LR3 stimulated cell growth in lab dishes. In a 1999 cattle study, slow infusion during underfeeding tended to conserve whole-body and muscle protein and changed blood amino acid and glucose levels. These are cell and animal findings, not confirmed human benefits. No controlled human trials are established in the supplied records.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A 2023 paper reported recombinant expression of IGF-1 and LR3 IGF-1 fusion constructs in Pichia pastoris.
Expression-system results do not verify this catalog manufacturing process.
Read the primary studyA 1999 study examined long(R3)-IGF-1 effects on protein metabolism in cattle.
Species, exposure and agricultural research context preclude human generalization.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 0.1 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 1 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Expression-system results do not verify this catalog manufacturing process.
View primary recordSpecies, exposure and agricultural research context preclude human generalization.
View primary recordThird-party publications selected for direct relevance.
Biotechnology study. 2023. PMID 37261455.
Animal study. 1999. PMID 10370861.
Concise answers for researchers comparing identity, evidence and catalog variants.
Published work is limited to production and animal research. A 2023 study made the analogue in yeast and showed purified material could stimulate cell growth in culture, supporting bioactivity. A 1999 cattle study found infusion tended to spare body and muscle protein in underfed heifers and changed blood amino acid, glucose and IGF profiles. The cited studies do not establish controlled human outcomes.
In a 1999 cattle study, slow infusion of long(R3)-IGF-1 during restricted feeding tended to conserve whole-body and muscle protein. Blood amino acids and glucose fell notably. Endogenous IGF-1 and IGF-2 dropped, while one binding protein rose. These shifts suggest altered nutrient use under catabolic conditions, but the findings come from beef heifers and cannot be assumed for humans or other species.
Direct evidence is limited to laboratory production and non-human models.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
Direct Long R3 IGF-1 literature is largely about recombinant production and animal biology. Some endpoints changed, while a 739-oocyte comparison found no difference in…
Updated October 1, 2026
Long R3 IGF-1 is an 83-amino-acid IGF-1 analogue with an Arg substitution at position 3 and a 13-residue N-terminal extension. It is not interchangeable…
Updated October 1, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: IG01 · 0.1 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
